Guardant Health, Inc.

Is Guardant Health, Inc. technically bullish or bearish?

As of August 7, 2025, Guardant Health, Inc. shows a bullish trend with strong MACD and KST indicators, despite mixed signals from the monthly RSI and Dow Theory, and has significantly outperformed the S&P 500 with a year-to-date return of 92.47% compared to 12.22%.

As of 7 August 2025, the technical trend for Guardant Health, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators from the MACD and KST on both weekly and monthly time frames. The daily moving averages also confirm a bullish trend. However, the monthly RSI is bearish, and the Dow Theory shows a mildly bearish signal on the weekly chart, indicating some mixed signals in the short term. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 significantly year-to-date with a return of 92.47% compared to the S&P 500's 12.22%, and over the past year, it has returned 134.45% against the S&P 500's 17.14%.

How big is Guardant Health, Inc.?

As of Jun 18, Guardant Health, Inc. has a market capitalization of $6.14 billion, with net sales of $774 million and a net profit of -$416.55 million over the last four quarters. Shareholder's funds are reported at -$139.65 million, and total assets amount to $1.49 billion.

As of Jun 18, Guardant Health, Inc. has a market capitalization of 6,136.17 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 774.00 million, while the sum of net profit for the same period is -416.55 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -139.65 million, and total assets amount to 1,485.61 million.

What does Guardant Health, Inc. do?

Guardant Health, Inc. is a precision oncology company that develops blood tests and analytics to aid in cancer treatment. As of March 2025, it reported net sales of $203 million and a net loss of $95 million, with a market cap of approximately $6.14 billion.

Overview: <BR>Guardant Health, Inc. is a precision oncology company focused on helping conquer cancer through its blood tests, data sets, and analytics, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 203 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -95 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 6,136.17 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.78 <BR>Return on Equity: 164.02% <BR>Price to Book: -24.47<BR><BR>Contact Details: <BR>Address: 505 Penobscot Dr, REDWOOD CITY CA: 94063-4737 <BR>Tel: ['1 650 2907575', '1 415 9375405'] <BR>Fax: 1 302 5313150 <BR>Website: http://www.guardanthealth.com

Should I buy, sell or hold Guardant Health, Inc.?

Who are in the management team of Guardant Health, Inc.?

As of March 2022, the management team of Guardant Health, Inc. includes AmirAli Talasaz (Chairman, President, COO), Helmy Eltoukhy (CEO, Director), Ian Clark (Lead Independent Director), and several independent directors: Vijaya Gadde, Bahija Jallal, Samir Kaul, and Stanley Meresman. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Guardant Health, Inc. includes the following individuals:<BR><BR>- Mr. AmirAli Talasaz: Chairman of the Board, President, Chief Operating Officer<BR>- Mr. Helmy Eltoukhy: Chief Executive Officer, Director<BR>- Mr. Ian Clark: Lead Independent Director<BR>- Ms. Vijaya Gadde: Director<BR>- Dr. Bahija Jallal: Independent Director<BR>- Mr. Samir Kaul: Independent Director<BR>- Mr. Stanley Meresman: Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.